Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. develops antibody-based medicines as a clinical-stage biotechnology company. Its updates center on antibody discovery and development programs in endocrinology, women’s health, immunology, oncology, and other areas, including work on complex targets such as GPCRs and ion channels.
Recurring news themes include clinical disclosures for ABCL635, an antibody therapeutic targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms associated with menopause. Company announcements also cover financial results, earnings-call materials, investor conference participation, platform and manufacturing updates, and patent licensing or litigation-resolution developments.
AbCellera (ABCL) has received authorization from Health Canada to proceed with Phase 1 clinical trials for ABCL635, their investigational antibody treatment targeting neurokinin 3 receptor (NK3R). The drug is being developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes, in menopausal women.
The Phase 1 trial, scheduled to begin in Q3 2025, will evaluate ABCL635's safety, pharmacokinetics, and pharmacodynamics in both healthy participants and postmenopausal women experiencing moderate-to-severe VMS. The company aims to provide a long-acting treatment option for millions of women affected by these disruptive menopausal symptoms.
AbCellera (ABCL) presented preclinical data for ABCL575, a novel anti-OX40L monoclonal antibody developed for treating moderate-to-severe atopic dermatitis, at the 2025 SID Annual Meeting. The drug demonstrated potent inhibition of inflammatory pathways and showed promising characteristics including:
- Equivalent functional activity to leading clinical benchmarks - Modified Fc domain supporting Fc-silencing and half-life extension - Predicted human half-life exceeding 60 days - Positive nonclinical safety profile - Favorable stability at high concentration
The company plans to advance ABCL575 to clinical trials within 2025, positioning it as a potential best-in-class treatment for atopic dermatitis with less frequent dosing requirements.
AbCellera (ABCL) reported its Q1 2025 financial results, highlighting the introduction of ABCL635, a potential first-in-class antibody for non-hormonal treatment of menopausal hot flashes. The company posted revenue of $4.2 million, down from $10.0 million in Q1 2024, and a net loss of $45.6 million ($0.15 per share) compared to $40.6 million loss in Q1 2024.
The company reached 97 partner-initiated program starts with downstreams (up 8% YoY) and increased its molecules in the clinic to 16 (up 23% YoY). AbCellera maintains strong liquidity with $810 million available, including $633 million in cash and equivalents and $178 million in non-dilutive government funding. The company plans to initiate Phase 1 clinical trials for both ABCL635 and ABCL575 in H2 2025.
AbCellera has unveiled promising preclinical data for its PSMA x CD3 T-cell engagers (TCEs) at the AACR Annual Meeting 2025. The research focuses on potential treatments for metastatic castration-resistant prostate cancer (mCRPC).
Key findings include:
- Potent tumor-cell killing ability, with one molecule showing ~10x higher EC50 than benchmark
- Sustained activity across four rounds of serial T-cell killing
- Significant tumor growth inhibition in xenograft mouse models
- Enhanced potency potential when combined with costimulatory PSMA x CD28 bispecifics
This marks the first demonstration of AbCellera's novel CD3-binders generating molecules with strong anti-tumor efficacy in vivo. The company's TCE platform strategy combines diverse CD3 and tumor-binding antibodies to develop optimized therapeutic candidates.
AbCellera (Nasdaq: ABCL) has announced its upcoming participation in two major investor conferences. The company will attend the Bloom Burton & Co. Healthcare Investor Conference scheduled for May 5-6, and the Goldman Sachs 46th Annual Global Healthcare conference taking place June 9-11. Interested parties can find more details on AbCellera's Investor Relations website.
AbCellera (ABCL) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025. The company will host an earnings conference call on the same day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Investors can access a live audio webcast of the earnings call through AbCellera's Investor Relations website, where a replay will also be made available after the conference.
AbCellera (ABCL) has announced an upcoming poster presentation at the American Association for Cancer Research (AACR) 116th Annual Meeting in Chicago. The presentation will showcase preclinical in vivo data on the company's PSMA x CD3 T-cell engagers for prostate cancer treatment.
The poster presentation, titled 'PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer' (Abstract #6012), will be presented in the Therapeutic Antibodies session on Tuesday, April 29, from 2:00 p.m. to 5:00 p.m. CDT at Section 35, Board 7 of the McCormick Place Convention Center.
AbCellera (ABCL) reported its full year 2024 financial results, marking a transition from a platform company to a clinical-stage biotech. The company recorded $28.8 million in total revenue, down from $38.0 million in 2023, and posted a net loss of $162.9 million ($0.55 per share) compared to $146.4 million loss in 2023.
Key operational highlights include reaching 96 partner-initiated programs (up from 87 in 2023) and advancing three additional molecules to the clinic, bringing the total to 16 clinical-stage molecules. The company maintains a strong liquidity position of $840 million, comprising $652.9 million in cash and equivalents plus $186 million in available non-dilutive government funding.
R&D expenses were $167.3 million, while G&A expenses increased to $72.7 million. The company is preparing to initiate Phase 1 trials for two programs, ABCL635 and ABCL575, and plans to start activities in its new clinical manufacturing facility in 2025.
AbCellera (ABCL) has announced its participation in two major investor conferences in March. The company will attend the 45th Annual TD Cowen Health Care Conference scheduled for March 3-5, and the KeyBanc Capital Markets Healthcare Forum taking place March 18-19. Interested parties can find more details on AbCellera's Investor Relations website.